Insight into the molecular regulation of the epithelial magnesium channel TRPM6

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 4, 2008, Pages 373-378

  Cao, Gang ^a   Hoenderop, Joost G J ^a   Bindels, René J M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Kinase domain; Epidermal growth factor; Estrogen, Mg2+ homeostasis; RACK1; TRPM6

Indexed keywords

CATION CHANNEL; EPIDERMAL GROWTH FACTOR; ESTROGEN; MAGNESIUM; RECEPTOR FOR ACTIVATED C KINASE 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL MELASTATIN SUBTYPE 6; UNCLASSIFIED DRUG; ION CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM6 PROTEIN, HUMAN;

AUTOPHOSPHORYLATION; CELL LEVEL; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; ENZYME REGULATION; FEEDBACK SYSTEM; HOMEOSTASIS; HUMAN; HYPOMAGNESEMIA; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; MAGNESIUM EXCRETION; MEMBRANE TRANSPORT; MINERAL BALANCE; MINERAL INTAKE; MOLECULAR BIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; DIET; EPITHELIUM; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; METABOLISM; PH; PHYSIOLOGY;

ANIMALS; DIET; EPITHELIUM; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN-ION CONCENTRATION; ION CHANNELS; KIDNEY; MAGNESIUM; TRPM CATION CHANNELS;

EID: 55249086295     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328303e184     Document Type: Review

References (59)

1. Hsu YJ, Hoenderop JG, Bindels RJ. TRP channels in kidney disease. Biochim Biophys Acta 2007; 1772:928-936.
2. Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys 2007; 458:33-39.
3. McKee JA, Brewer RP, Macy GE, et al. Magnesium neuroprotection is limited in humans with acute brain injury. Neurocrit Care 2005; 2:342-351.
4. Tam M, Gomez S, Gonzalez-Gross M, Marcos A. Possible roles of magnesium on the immune system. Eur J Clin Nutr 2003; 57:1193-1197.
5. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol (in press).
6. Sontia B, Touyz RM. Magnesium transport in hypertension. Pathophysiology 2007; 14:205-211.
7. Konrad M, Schlingmann KP, GudermannT. Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 2004; 286:F599-F605.
8. Dai LJ, Ritchie G, Kerstan D, et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001; 81:51-84.
9. Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Intestinal absorption of magnesium from food and supplements. J Clin Invest 1991; 88:396-402.
10. Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int 1997; 52:1180-1195.
11. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31:166-170.
12. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemiawithsecondaryhypocalcemia.NatGenet2002;31:171-174.
13. 2+ content and estrogens. J Am Soc Nephrol 2006; 17:1035-1043.
14. 2+ absorption. J Biol Chem 2004; 279:19-25.
15. 2+ homeostasis by TRPM7. Cell 2003; 114:191-200.
16. Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol 2006; 127:525-537.
17. Chubanov V, Waldegger S, Mederos Y, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnese-mia with secondary hypocalcemia. Proc Natl Acad Sci USA 2004; 101:2894-2899.
18. Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 2001; 291:1043-1047.
19. Topala CN, Groenestege WT, Thebault S, et al. Molecular determinants of permeation through the cation channel TRPM6. Cell Calcium 2007; 41:513-523.
20. 2+ perme ability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem 2007; 282:25817-25830.
21. Bogoroch R, Belanger LF. Skeletal effects of magnesium deficiency in normal, ovariectomized, and estrogen-treated rats. Anat Rec 1975; 183:437-447.
22. McNair P, Christiansen C, Transbol I. Effect of menopause and estrogen substitutional therapy on magnesium metabolism. Miner Electrolyte Metab 1984; 10:84-87.
23. Muneyyirci-Delale O, Nacharaju VL, Dalloul M, et al. Serum ionized magnesium and calcium in women after menopause: inverse relation of estrogen with ionized magnesium. Fertil Steril 1999; 71:869-872.
24. Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J Am Coll Nutr 1994; 13:429-446.
25. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147:5557-5563.
26. Fu XD, Simoncini T. Nongenomic sex steroid actions in the vascular system. Semin Reprod Med 2007; 25:178-186.
27. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci 2006; 1089:424-430.
28. Zheng FF, Wu RC, Smith CL, O'Malley BW. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol 2005; 25:8273-8284.
29. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117:2260-2267.
30. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387-394.
31. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin Colorectal Cancer 2004; 3:205.
32. Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004; 64:109-118; discussion 119-121.
33. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005; 27:684-694.
34. van de Graaf SF, Hoenderop JG, Bindels RJ. Regulation of TRPV5 andTRPV6 by associated proteins. Am J Physiol Renal Physiol 2006; 290:F1295-F1302.
35. Bezzerides VJ, Ramsey IS, Kotecha S, et al. Rapid vesicular translocation and insertion of TRP channels. Nat Cell Biol 2004; 6:709-720.
36. Odell AF, Scott JL, Van Helden DF. Epidermal growth factor induces tyrosine phosphorylation, membrane insertion, and activation of transient receptor potential channel 4. J Biol Chem 2005; 280:37974-37987.
37. Romani A. Regulation of magnesium homeostasis and transport in mammalian cells. Arch Biochem Biophys 2007; 458:90-102.
38. Cao G, Thebault S, van der Wijst J, et al. RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha-kinase domain. Curr Biol 2008; 18:168-176.
39. McCahill A, Warwicker J, Bolger GB, et al. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 2002; 62:1261-1273.
40. Chen S, Lin F, Hamm HE. RACK1 binds to a signal transfer region of G betagamma and inhibits phospholipase C beta2 activation. J Biol Chem 2005; 280:33445-33452.
41. Sklan EH, Podoly E, Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol 2006; 78:117-134.
42. 2+ channel TRPV6. J Biol Chem 2006; 281:29669-29674.
43. 2+ channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex. EMBO J 2003; 22:1478-1487.
44. Ryazanov AG. Elongation factor-2 kinase and its newly discovered relatives. FEBS Lett 2002; 514:26-29.
45. Drennan D, Ryazanov AG. Alpha-kinases: analysis of the family and comparison with conventional protein kinases. Prog Biophys Mol Biol 2004; 85:1-32.
46. Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J. Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell 2001; 7:1047-1057.
47. Schmitz C, Dorovkov MV, Zhao X, et al. The channel kinases TRPM6 and TRPM7 are functionally nonredundant. J Biol Chem 2005; 280:37763-37771.
48. Levitan IB. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol 1994; 56:193-212.
49. Touyz RM, He Y, Montezano AC, et al. Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG II in vascular smooth muscle cells from spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2006; 290:R73-R78.
50. Clark K, Langeslag M, van Leeuwen B, et al. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J 2006; 25:290-301.
51. Schmitz C, Dorovkov MV, Zhao X, et al. The channel kinases TRPM6 and TRPM7 are functionally nonredundant. J Biol Chem 2005; 280:37763-37771.
52. Matsushita M, Kozak JA, Shimizu Y, et al. Channel function is dissociated from the intrinsic kinase activity and autophosphorylation of TRPM7/ChaK1. J Biol Chem 2005; 280:20793-20803.
53. Takezawa R, Schmitz C, Demeuse P, et al. Receptor-mediated regulation of the TRPM7 channel through its endogenous protein kinase domain. Proc Natl Acad Sci U S A 2004; 101:6009-6014.
54. 2+ transport proteins. J Am Soc Nephrol 2006; 17:617-626.
55. 2+ transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004; 15:549-557.
56. Ikari A, Okude C, Sawada H, et al. Down-regulation of TRPM6-mediated magnesium influx by cyclosporin A. Naunyn Schmiedebergs Arch Pharmacol 2007; 17 Nov [Epub ahead of print].
57. 2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115: 1651-1658.
58. Cole DE, Quamme GA. Inherited disorders of renal magnesium handling. J Am Soc Nephrol 2000; 11:1937-1947.
59. Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 2003; 14:249-260.